Cipla receives USFDA approval for Sevelamer Carbonate tablets
Tanay Loya / 27 Oct 2017
Cipla Ltd, a global pharmaceutical company, announced that it has received USFDA approval for Sevelamer Carbonate tablets.
Cipla Ltd, a global pharmaceutical company, announced that it has received USFDA approval for Sevelamer Carbonate tablets.
The company announced that its subsidiary InvaGen Pharmaceuticals has received final approval for its abbreviated new drug application (ANDA) for Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration (USFDA) for marketing a generic version of the said tablet.
The tablets is used for controlling serum phosphorus in adults with chronic kidney disease on dialysis.
The company in its press release said that it will be immediately commencing the commercial launch of the tablets.
Sevelamer Carbonate Tablets are an AB-rated generic equivalent to Renvela tablets, 800 mg of Genzyme Corporation which had US sales of approximately USD 1.85 billion for the 12-month period ending August 2017.
At 10:02 am, Cipla was trading at Rs 622.70 per share, up Rs. 11.20 or 1.83 per cent from its previous closing price of Rs. 611.50. The scrip opened at Rs. 625 per share and touched a high and low of Rs. 625.80 and Rs. 618.25, respectively on the NSE. The scrip attracted a traded volume of 5,25,992 shares on the NSE.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.